Abstract
Glioma is the most common malignant intracranial tumour. Recently, several publications have suggested that miRNAs can be used as potential diagnostic biomarkers of glioma. Here we performed a meta-analysis to identify the diagnostic accuracy of differentially expressed circulating miRNAs in gliomas. Using PubMed, Medline and Cochrane databases, we searched for studies which evaluated a single or panel of miRNAs from circulating blood as potential biomarkers of glioma. Sixteen publications involving 23 studies of miRNAs from serum or plasma met our criteria and were included in this meta-analysis. The pooled diagnostic parameters were calculated by random effect models and overall diagnostic performance of altered miRNAs was illustrated by the summary receiver operator characteristic (SROC) curves. The pooled sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratio (NLR) from each study were calculated. The pooled PLR, NLR and Diagnostic Odds Ratio were 6.39 (95% CI, 4.61–8.87), 0.15 (95% CI, 0.11–0.21) and 41.91 (95% CI, 23.15–75.88), respectively. The pooled sensitivity, specificity and area under the curve (AUC) were 0.87 (95% CI, 0.82–0.91), 0.86 (95% CI, 0.82–0.90) and 0.93 (95% CI, 0.91–0.95), respectively. This meta-analysis demonstrated that circulating miRNAs are capable of distinguishing glioma from healthy controls. Circulating miRNAs are promising diagnostic biomarkers for glioma and can potentially be used as a non-invasive early detection.
Highlights
Glioma, the most prevalent malignant cancer in the central nervous system, has a content of latent progression before histopathological diagnosis [1]
Key words including “glioma” or “glioblastoma”, “microRNA” or “miRNA” or “miR” and “plasma” or “serum” or “circulating” or “blood”, which worked as Medical Subject Headings (MeSH) and free-style words in searching retrieval
One other article was excluded as it studied diagnostic accuracy of circulating miRNA between glioblastoma and low grade glioma rather than miRNA biomarker in tumour and normal control
Summary
The most prevalent malignant cancer in the central nervous system, has a content of latent progression before histopathological diagnosis [1]. The incidence of glioma in adults varies from 1.32 to 5.73 per 100, 000 person, depending on geographic location [2]. Glioma is categorized according to the World Health Organization (WHO) grading system, grade I and II are classified as benign and low grade glioma while grade III and IV are high grade glioma. The current protocolized treatment for high grade glioma is surgery followed by concurrent radiotherapy and temozolomide chemotherapy [3]; despite this, glioma remains a highly.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
